Cargando…

Dose‐Finding Studies Among Orphan Drugs Approved in the EU: A Retrospective Analysis

In the development process for new drugs, dose‐finding studies are of major importance. Absence of these studies may lead to failed phase 3 trials and delayed marketing authorization. In our study we investigated to what extent dose‐finding studies are performed in the case of orphan drugs for metab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schuller, Yvonne, Gispen‐de Wied, Christine, Hollak, Carla E. M., Leufkens, Hubertus G. M., Stoyanova‐Beninska, Violeta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Orphan Drugs
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585723/ https://www.ncbi.nlm.nih.gov/pubmed/30192386 http://dx.doi.org/10.1002/jcph.1304

Ejemplares similares

Oncologic orphan drugs approved in the EU – do clinical trial data correspond with real-world effectiveness?
por: Schuller, Yvonne, et al.
Publicado: (2018)

Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic Diseases
por: Schuller, Y., et al.
Publicado: (2017)

Regulatory Standards in Orphan Medicinal Product Designation in the EU
por: Tsigkos, Stelios, et al.
Publicado: (2021)

Reducing exacerbations in children and adults with primary ciliary dyskinesia using erdosteine and/or azithromycin therapy (REPEAT trial): study protocol for a multicentre, double-blind, double-dummy, 2×2 partial factorial, randomised controlled trial
por: Chang, Anne B, et al.
Publicado: (2022)

Validation of a health-related quality of life instrument for primary ciliary dyskinesia (QOL-PCD)
por: Behan, Laura, et al.
Publicado: (2017)

Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy
por: Franzen, Daniel, et al.
Publicado: (2018)

FLCN-regulated miRNAs suppressed reparative response in cells and pulmonary lesions of Birt-Hogg-Dubé syndrome
por: Min, Haiyan, et al.
Publicado: (2020)

Cardiopulmonary function in adolescent patients with pectus excavatum or carinatum
por: Ramadan, Salim, et al.
Publicado: (2021)

Nationwide retrospective observational study of idiopathic dendriform pulmonary ossification: clinical features with a progressive phenotype
por: Nishioka, Yasuhiko, et al.
Publicado: (2022)

ABCA3-related interstitial lung disease beyond infancy
por: Li, Yang, et al.
Publicado: (2023)

Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation
por: Mulder, Jorn, et al.
Publicado: (2021)

Leveraging existing opportunities for improved Orphan Drug approval in the EU
por: Edfjäll, Catarina
Publicado: (2012)

Predictors of orphan drug approval in the European Union
por: Heemstra, Harald E., et al.
Publicado: (2008)

No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
por: Stolk, Pieter, et al.
Publicado: (2009)

The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review
por: Schuller, Y., et al.
Publicado: (2015)

Predictors of orphan drug approval
por: Heemstra, Harald
Publicado: (2010)

Editorial: The use of real world data for regulatory purposes in the rare diseases setting
por: Giannuzzi, Viviana, et al.
Publicado: (2022)

Regulatory scientific advice in drug development: does company size make a difference?
por: Putzeist, Michelle, et al.
Publicado: (2010)

Investigating the landscape of US orphan product approvals
por: Miller, Kathleen L., et al.
Publicado: (2018)

Lifecycle management of orphan drugs approved in Japan
por: Seki, Kiyoshi, et al.
Publicado: (2022)

Editorial: Reviews in: regulatory science
por: Kerpel-Fronius, Sandor, et al.
Publicado: (2023)

Drug Shortages From the Perspectives of Authorities and Pharmacy Practice in the Netherlands: An Observational Study
por: Postma, Doerine J., et al.
Publicado: (2018)

An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function
por: Moore, Kenneth T, et al.
Publicado: (2014)

Drug development for exceptionally rare metabolic diseases: challenging but not impossible
por: Putzeist, Michelle, et al.
Publicado: (2013)

Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit
por: Mulder, J., et al.
Publicado: (2023)

Clinical evidence for orphan medicinal products-a cause for concern?
por: Picavet, Eline, et al.
Publicado: (2013)

Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit–The EU Regulator's Perspective
por: Sheean, Maria E., et al.
Publicado: (2021)

Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Approaches and Future Directions
por: Mitchell, Ellen L., et al.
Publicado: (2017)

Bone Involvement in Rosai-Dorfman Disease (RDD): a Case Report and Systematic Literature Review
por: Mosheimer, Birgit A., et al.
Publicado: (2017)

Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders
por: Hollak, Carla EM, et al.
Publicado: (2011)

Successful treatment of excessive dose of carbamazepine
por: Yaylacı, Selcuk, et al.
Publicado: (2012)

Onychomycosis: An Updated Review
por: Leung, Alexander K.C., et al.
Publicado: (2020)

A curious finding of skin blebs: A case report
por: Toteja, Nisha, et al.
Publicado: (2019)

Dose-dependent valproate-induced alopecia in patients with mental disorders
por: Tomita, Takashi, et al.
Publicado: (2015)

The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US/EU and in Latin America
por: Arnold, Renée J.G., et al.
Publicado: (2015)

Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective
por: Tomeo, Francesca, et al.
Publicado: (2021)

Registries for orphan drugs: generating evidence or marketing tools?
por: Hollak, Carla E. M., et al.
Publicado: (2020)

Black hairy tongue with a fixed dose combination of olanzapine and fluoxetine
por: Jhaj, Ratinder, et al.
Publicado: (2016)

Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects
por: Mukai, Mayumi, et al.
Publicado: (2017)

Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders
por: Mulder, Jorn, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ihr6a2k03i14rnqqub1biio614